Outset Medical Shares Rise 56% After FDA Grants Clearance for TabloCart
By Chris Wack
Outset Medical shares were up 56% to $4.89 after the company said that the Food and Drug Administration has granted 510(k) clearance of its TabloCart with prefiltration, an optional accessory for the Tablo Hemodialysis System.
The stock hit its 52-week low of $1.92 on April 15, and is down 76% in the past 12 months.
The medical technology company said it has resumed distribution of TabloCart with prefiltration and has product available to ship to customers in the U.S.
Outset's TabloCart is designed to improve user experience within healthcare facilities. It is available in two versions: one with added storage and another featuring water prefiltration capabilities, meeting diverse clinical needs, the company says.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
May 06, 2024 10:53 ET (14:53 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
How Anti-Obesity Drugs Are Innovating the Healthcare Market
-
What’s Happening In the Markets This Week
-
Why Immigration Has Boosted Job Gains and the Economy
-
What to Invest in During High Inflation
-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
Markets Brief: All Eyes On Inflation
-
After Earnings, Is Lyft Stock a Buy, a Sell, or Fairly Valued?
-
8 Stock Picks in the Apparel Industry
-
Baidu Earnings: Advertising Weakness Offset by Continued Growth In Cloud Business
-
Going Into Earnings, Is Target Stock a Buy, a Sell, or Fairly Valued?
-
Walmart Earnings: Low Prices and Strong Digital Presence Drive Market Share Gains
-
After Earnings and a Big Selloff, Is Shopify Stock a Buy, a Sell, or Fairly Valued?
-
Cisco Earnings: Positive Guidance and Splunk Inclusion Align With Our Long-Term Thesis
-
3 Warren Buffett Stocks to Buy After Berkshire Hathaway’s Just-Released 13F Filing